Filing Flows

Filing Flows › Monte Rosa Therapeutics (GLUE) › Who owns the stock

Who owns Monte Rosa Therapeutics (GLUE) stock

183 funds reported Monte Rosa Therapeutics (GLUE) shares in their latest 13F filings, worth $2.2B in all. The largest holder is Price T Rowe Associates ($214M). Last quarter 100 funds added to their stakes and 76 cut them.

Largest holders of GLUE (13F)Largest holders of GLUE (13F)Price T Rowe Associates$214MNEA Management Company, LLC$186MBlackRock$166MTCG Crossover Management, LLC$112MVestal Point Capital, LP$111MBVF$108MBaker Bros. Advisors LP$105MState Street$90.3MSuvretta Capital Management, LLC$85.9MVanguard Capital Management LLC$82.6M

Largest holders (13F)

FundSharesValueChangeQuarter
Price T Rowe Associates8,861,171$214Mincrease2026-06-30
NEA Management Company, LLC7,692,298$186Munchanged2026-06-30
BlackRock6,843,087$166Mincrease2026-06-30
TCG Crossover Management, LLC4,622,151$112Munchanged2026-06-30
Vestal Point Capital, LP4,600,000$111Mincrease2026-06-30
BVF4,460,886$108Munchanged2026-06-30
Baker Bros. Advisors LP4,345,736$105Munchanged2026-06-30
State Street3,731,416$90.3Mincrease2026-06-30
Suvretta Capital Management, LLC3,549,539$85.9Mdecrease2026-06-30
Vanguard Capital Management LLC3,412,927$82.6Mincrease2026-06-30
Versant Venture Management, LLC3,180,780$77.0Munchanged2026-06-30
Vanguard Group3,246,500$50.9Mincrease2025-12-31
Geode Capital Management, LLC1,864,113$45.1Mincrease2026-06-30
American Century Companies1,622,846$39.3Mdecrease2026-06-30
Marshall Wace, LLP1,593,600$38.6Mincrease2026-06-30

Monte Rosa Therapeutics' latest quarter

Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most GLUE stock?

By the latest 13F filings: Price T Rowe Associates ($214M); NEA Management Company, LLC ($186M); BlackRock ($166M); TCG Crossover Management, LLC ($112M); Vestal Point Capital, LP ($111M).

What is the short interest in GLUE?

20,660,257 shares were sold short at the 2026-10-15 settlement, 4.95% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.